<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01798602</url>
  </required_header>
  <id_info>
    <org_study_id>CCCTG</org_study_id>
    <nct_id>NCT01798602</nct_id>
  </id_info>
  <brief_title>Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial</brief_title>
  <acronym>CHAT Pilot</acronym>
  <official_title>Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Canadian Critical Care Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Physicians' Services Incorporated Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Public Health Agency of Canada (PHAC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Canadian Critical Care Trials Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CHAT Pilot Trial is designed to compare rosuvastatin against placebo in patients with
      suspected H1N1. The pilot study will assess the feasibility of our clinical protocols, and
      study procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a pilot study to assess the feasibility and acceptability of a double blind
      randomized controlled trial (RCT) evaluating the efficacy of rosuvastatin as adjuvant therapy
      for H1N1 influenza
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    H1N1 pandemic concluded
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of eligible patients enrolled in the CHAT study</measure>
    <time_frame>Over 6 month period or during H1N1 pandemic</time_frame>
    <description>This was a pilot study whose primary goal was to evaluate the feasibility of patient recruitment during an emerging pandemic</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence to the medication administration regimen as outlined in the study protocol.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of completed primary and secondary endpoints for the planned full CHAT trial that are collected.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of study withdrawals due to administration of open label statins and withdrawals of consent.</measure>
    <time_frame>Up to 28 days or until hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recruitment rates by consent model.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>H1N1 Influenza</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 40 mg via nasogastric tube then 20 mg po or via nasogastric tube daily for 14 days or until hospital discharge Placebo is identical capsule with no active drug
Both are crushed for administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical drug vehicle with no active agent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin or identical placebo</intervention_name>
    <description>Tablet crushed for administration via feeding tube</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical placebo for rosuvastatin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Critically ill adult patients &gt; 16 years of age admitted to an adult ICU for any
             reason with suspected, probable or confirmed novel swine origin influenza A/H1N1
             infection

          -  Requiring mechanical ventilation (invasive or non-invasive)

          -  Receiving antiviral therapy (any medication at any dose and for any intended duration)
             for &lt; 72 hours

          -  Clinicians must have a 'moderate', 'high' or 'moderate to high' index of suspicion for
             H1N1

        Exclusion Criteria:

          -  Age &lt; 16 years

          -  Do not resuscitate or re-intubate order documented on chart or anticipated withdrawal
             of life support

          -  Weight &lt; 40 kg

          -  Unable to receive or unlikely to absorb enteral study drug (e.g. incomplete or
             complete bowel obstruction, intestinal ischemia, infarction, short bowel syndrome)

          -  Rosuvastatin specific exclusions:

               1. Already receiving a statin (Atorvastatin, Lovastatin, Simvastatin, Pravastatin,
                  Rosuvastatin)

               2. Allergy or intolerance to statins

               3. Receiving niacin, fenofibrate, cyclosporine, gemfibrozil, lopinavir, ritonavir or
                  planned use of oral contraceptives or estrogen therapy during the ICU stay

               4. CK exceeds 10 times ULN or ALT exceeds 8 times the ULN

          -  Severe chronic liver disease (Child-Pugh Score 11-15) (see Appendix 6)

          -  Previous enrolment in this trial

          -  Pregnancy or breast feeding

          -  At the time of enrolment, patients must not have received &gt;72 hours of antiviral
             therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.infactglobal.org</url>
    <description>International Forum for Acute Care Trialists Website</description>
  </link>
  <link>
    <url>http://www.ccctg.ca</url>
    <description>Canadian Critical Care Trials Group</description>
  </link>
  <reference>
    <citation>Burns KE, Chant C, Smith O, Cuthbertson B, Fowler R, Cook DJ, Kruger P, Webb S, Alhashemi J, Dominguez-Cherit G, Zala C, Rubenfeld GD, Marshall JC. A Canadian Critical Care Trials Group project in collaboration with the international forum for acute care trialists - Collaborative H1N1 Adjuvant Treatment pilot trial (CHAT): study protocol and design of a randomized controlled trial. Trials. 2011 Mar 9;12:70. doi: 10.1186/1745-6215-12-70.</citation>
    <PMID>21388549</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2013</study_first_submitted>
  <study_first_submitted_qc>February 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2013</study_first_posted>
  <last_update_submitted>February 22, 2013</last_update_submitted>
  <last_update_submitted_qc>February 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>H1N1</keyword>
  <keyword>Rosuvastatin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

